PI
CERE

Putnam Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Putnam Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-16,239
Closed -$527K – 1285
2021
Q4 		$527K Buy
+16,239
New +$573K ﹤0.01% 980

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Putnam Investments's CERE Position: Q1 2022 in Review

Putnam Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022, closing a stake of 16,239 shares — an estimated $527K sold.

Putnam Investments first reported a position in CERE in Q4 2021 and held it in 1 quarter. The position peaked at $527K in Q4 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

  • Putnam Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Putnam Investments sold 16,239 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $527K.
  • Putnam Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Putnam Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $527K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Putnam Investments's 13F filing for Q1 2022, filed 16 May 2022.